Gulf Pain Management Drugs Market Statistics 2020-2027:
The Gulf Pain Management Drugs Market size was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.
Pain is an uncomfortable sensory and emotional sensation caused due to tissue injury or disease. It is caused due to injury and various diseases such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer, fibromyalgia and cancer. It can be defined as acute pain and chronic pain depending on duration.
This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is anticipated to impact the growth of the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems in the Gulf countries, so that pain services in many clinics are no longer open for public services because of safety. Furthermore, the demand for pain management drugs is expected to rise during the latter half of the forecast period owing to telemedicine which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain. Through telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief.
Chronic pain is mainly caused due to aging conditions of bone and joints and nerve damage and injury. Pain is managed by a particular set of drugs to reduce the symptoms or treat pain. Pain process is complex and there are various drugs that provide relief by acting through a variety of physiological mechanism. Opioids are the most prescribed pain medication. These are narcotic pain medications containing natural and synthetic opiates. Opioids are usually used for acute pain, such as short-term pain after surgery. Morphine, Fentanyl, Oxycodone and Codeine are some of the opioids used for pain management.
As per the statista, In the UAE, 4,500 new cancer cases are diagnosed each year, with cancers being the third leading cause of death after cardiovascular illnesses and injuries. This is expected to increase the need of cancer pain drugs for therapeutic purposes, thus fueling the gulf pain management drugs market growth.
In recent times there is increased use of pain management drugs due to rise in aging population. Increasing prevalence of diseases such as cancer, diabetic neuropathy, osteoarthritis and chronic arthritis, increasing number of surgical procedures and increasing healthcare expenditure are some of the key factors driving the growth for the gulf pain management drugs market. In addition, increasing healthcare awareness is also fueling the growth of gulf pain management drugs market. However, increase in generic completion, patent expiration of blockbuster drugs and availability of substitutes such as pain relief devices are some of the major factors restraining the growth for gulf pain management drugs market. In addition, prescribing drug abuse would inhibit the growth of the market.
Increasing R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to market growth. In addition, novel molecule combination and drug delivery techniques would develop opportunity for the gulf pain management drugs market. However, side effects of pain management drugs could lead a challenge for the pain management drugs market.
By Drug Class
Opioids holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.
Gulf Pain Management Drugs Market Segmentation
The gulf pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications. On the basis of pain type, it is segmented into chronic pain and acute pain. On the basis of country, it is divided into UAE, Saudi Arabia, Oman and rest of Gulf countries.
Gulf pain Management Drugs Market Segment review
On the basis of drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anti-migraine agents segment is anticipated to possess highest growth rate during the forecast period.
By Indication
Neuropathic Pain segment is projected as one of the most lucrative segments.
By indication, the neuropathic pain segment accounted for a majority of the gulf pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain segment are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries and rise in prevalence of chronic diseases that lead to back pain.
The key players operating in the Gulf Pain Management Drugs Market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, Gulf Pharmaceutical Industries (Julphar), Oman pharmaceutical products co. Llc and GlaxoSmithKline Plc.
By Country
Saudi Arabia holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the gulf pain management drugs market, with current trends and future estimations to elucidate the imminent investment pockets.
- Quantitative analysis from 2019 to 2027 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- The gulf pain management drugs market size and estimations are based on a comprehensive analysis of key developments in the industry.
- Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the market framework.
Gulf Pain Management Drugs Market, by Drug Class, Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Indication |
|
 By Pain Type |
|
 By Country |
|
 Key Market Players | GLAXOSMITHKLINE PLC (GSK), PFIZER INC., MERCK & CO., INC., GULF PHARMACEUTICAL INDUSTRIES (JULPHAR), JOHNSON & JOHNSON, ELI LILY AND COMPANY, NOVARTIS INTERNATIONAL AG, MYLAN N.V., OMAN PHARMACEUTICAL PRODUCTS CO. LLC, ABBOTT LABORATORIES |
Analyst Review
The demand for pain management drugs has increased rapidly over the recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors toward the market growth. Presence of large geriatric population base, rise in prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to the growth of the market.
However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.
The increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers in the Gulf countries. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as The Gulf Cooperation Council (GCC) supplement the market growth. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
The demand for pain management drugs has increased rapidly over the recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors toward the market growth. Presence of large geriatric population base, rise in prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to the growth of the market.
However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.
The increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers in the Gulf countries. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as The Gulf Cooperation Council (GCC) supplement the market growth. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
Pain is a general term that describes uncomfortable sensations in the body. It stems from activation of the nervous system. Pain can range from annoying to debilitating, and it can feel like a sharp stabbing or a dull ache. Pain can also be described as throbbing, stinging, sore, and pinching.
A wide range of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain).
The total market value of Gulf Pain Management Drugs Market is $851.08 million in 2019.
The forcast period for Gulf Pain Management Drugs Market is 2020 to 2027
Top companies such as Pfizer, Eli Lilly, GSK and others held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
In drug class segment Opioids is the most influencing segment. This is attributed to surge in prevalence of hematological diseases and rise in accidents.
The market value of Gulf Pain Management Drugs Market in 2027 is $1,047.91 million.
The base year is 2019 in Gulf Pain Management Drugs Market
The major factor that fuels the growth of the global Gulf Pain Management Drugs Market includes rise in incidences of chronic diseases, favorable regulatory scenario, and increase in geriatric population drive the growth of the Gulf pain management drugs market.However, Availability of alternative therapies and drug exploitation are expected to hamper the market growth.
Increase in R&D activities for development of novel drugs with fewer side-effects and regulatory authorities designate certain rapid-track production drugs to speed up regulatory approvals and market entry processes. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities.
Loading Table Of Content...
